Skip to main content

Biofrontera Inc.

corporate_fare Company Profile

Biofrontera Inc.

BFRI·NASDAQ·Life Sciences·CIK 0001858685

Biofrontera Inc. is a United States-based biopharmaceutical company that develops, manufactures, and commercializes pharmaceutical products for dermatological conditions, with a focus on photodynamic therapy (PDT). The company's products include Ameluz and the BF-RhodoLED and RhodoLED XL lamp series, collectively known as the "RhodoLED Lamps." These products are used to treat actinic keratosis (AK), a common skin condition characterized by pre-cancerous lesions. Biofrontera Inc. generates revenue by selling its products directly to dermatology offices and groups through its national commercial team. The company was formed in 2015 as a Delaware corporation and a wholly owned subsidiary of Biofrontera AG, a German stock corporation. Biofrontera Inc. completed its initial public offering in 2021. Effective June 1, 2024, the company assumed control of all clinical trials for Ameluz in the United States, managing costs and trial efficiency through Discovery, its wholly owned subsidiary formed in Germany in 2022. Research and development programs focus on expanding the label for Ameluz and enhancing the capabilities of the RhodoLED Lamps to support PDT growth and meet dermatologists' needs. On October 20, 2025, Biofrontera Inc. acquired all rights in the United States to Ameluz and RhodoLED from the Biofrontera Group through an Asset Purchase Agreement and an Earnout Agreement. On November 6, 2025, the company completed the sale of the intangible asset related to its Xepi product line.

Biofrontera Inc. (NASDAQ:BFRI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for BFRI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for BFRI spans 8-K, 10-Q, DEF 14A, 10-K.

Recent high-impact activity:

  • Biofrontera Hit With Nasdaq Bid-Price Deficiency Notice, 180 Days to Reach $1.00
  • Biofrontera Q3: Revenue Up 30% to $9.1M, But Going Concern and New Nasdaq Equity Deficiency
  • Biofrontera Posts $9.1M Q3 Revenue but Swings to $6.4M Net Loss
  • Biofrontera Seeks FDA Nod to Expand Ameluz Use to Full-Body Actinic Keratoses
  • FDA Clears Ameluz for Skin Cancer, a First for Photodynamic Therapy

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$41.7M
Net Income
-$10.54M
Diluted EPS
-$1.04
Op. Cash Flow
-$13.36M
Free Cash Flow
-$13.36M
Operating Income
-$11.35M
Cash & Equivalents
$6.39M
Debt / Equity
0.00×
Net Margin
-25.3%
Shares Outstanding
11.65M sh
Source: 10-K · filed 2026-03-19 · accession 0001493152-26-011625

Short Interest & Short Volume

1.30 days to cover

FINRA reported short interest of 189,627 shares in BFRI as of the October 30, 2026 settlement, a 83.8% increase from the prior period — about 1.3 days to cover at its recent average daily volume. On November 20, 2026, 32.0% of BFRI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)189,627 shares as of October 30, 2026
Change vs prior period▲ 83.8%
Days to cover1.30 at avg daily volume of 146,358
Daily short volume (FINRA facilities)32.0% of 132,672 shares on November 20, 2026
5-day average short volume37.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for BFRI, detected from its recent SEC filings · based on capital-structure filings through 2026-06-17.

Shareholder Meeting Results · Equity Incentive Plan Expanded

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$0.5401 +1.91% today
52-week range · as of 2026-11-20 $0.53 – $1.66
Market cap
$9.51M
Volume
196.1K (1.0× avg)
3-mo avg 199.1K
Live data · 2026-11-22 06:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BFRI - Latest Insights

BFRI
Nov 20, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.530
Real-time Price: $0.5401 info
Change: +$0.0101 (+2%) info
Market Cap: $9.513M info
BFRI
Nov 13, 2026, 4:46 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.700
Real-time Price: $0.5401 info
Change: -$0.1599 (-23%) info
Market Cap: $9.513M info
BFRI
Nov 13, 2026, 8:03 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.813
Real-time Price: $0.5401 info
Change: -$0.2729 (-34%) info
Market Cap: $9.513M info
BFRI
Oct 08, 2026, 9:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.9722
Real-time Price: $0.5401 info
Change: -$0.4321 (-44%) info
Market Cap: $9.513M info
BFRI
Sep 14, 2026, 9:29 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.55
Real-time Price: $0.5401 info
Change: -$1.01 (-65%) info
Market Cap: $9.513M info
BFRI
Aug 13, 2026, 4:41 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.27
Real-time Price: $0.5401 info
Change: -$0.7299 (-57%) info
Market Cap: $9.513M info
BFRI
Aug 13, 2026, 8:51 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.5401 info
Change: -$0.6999 (-56%) info
Market Cap: $9.513M info
BFRI
Jun 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.9899
Real-time Price: $0.5401 info
Change: -$0.4498 (-45%) info
Market Cap: $9.513M info
BFRI
May 14, 2026, 4:28 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.5401 info
Change: -$0.4099 (-43%) info
Market Cap: $9.513M info
BFRI
May 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.01
Real-time Price: $0.5401 info
Change: -$0.4699 (-47%) info
Market Cap: $9.513M info
BFRI
May 14, 2026, 7:40 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.9996
Real-time Price: $0.5401 info
Change: -$0.4595 (-46%) info
Market Cap: $9.513M info
BFRI
Apr 30, 2026, 4:40 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.5401 info
Change: -$0.5399 (-50%) info
Market Cap: $9.513M info
BFRI
Mar 19, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.8556
Real-time Price: $0.5401 info
Change: -$0.3155 (-37%) info
Market Cap: $9.513M info
BFRI
Mar 19, 2026, 9:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8617
Real-time Price: $0.5401 info
Change: -$0.3216 (-37%) info
Market Cap: $9.513M info
BFRI
Mar 19, 2026, 9:25 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.848
Real-time Price: $0.5401 info
Change: -$0.3079 (-36%) info
Market Cap: $9.513M info
BFRI
Mar 09, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.925
Real-time Price: $0.5401 info
Change: -$0.3849 (-42%) info
Market Cap: $9.513M info
BFRI
Mar 09, 2026, 9:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8914
Real-time Price: $0.5401 info
Change: -$0.3513 (-39%) info
Market Cap: $9.513M info
BFRI
Feb 26, 2026, 9:20 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.910
Real-time Price: $0.5401 info
Change: -$0.3699 (-41%) info
Market Cap: $9.513M info
BFRI
Feb 09, 2026, 9:20 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.02
Real-time Price: $0.5401 info
Change: -$0.480 (-47%) info
Market Cap: $9.513M info
BFRI
Jan 13, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.7851
Real-time Price: $0.5401 info
Change: -$0.245 (-31%) info
Market Cap: $9.513M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets